Monday, January 28, 2013

Investopedia: Shabby Reporting And Questionable Prospects At Abbott Labs

There's no one right way for a company to report results to investors, but I believe Abbott Laboratories' (NYSE:ABT) reporting is significantly sub-standard given the approaching split into Abbott Laboratories and AbbVie (NYSE:ABBV). Even worse, however, is the apparent state of Abbott Laboratories' business. While I can support the idea that there's room for growth and self-improvement, investors need to realize that Humira hid a lot of defects and that Abbott may not be the top-notch company people generally assumed it was.

Please click below to continue:

No comments: